Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Sales and Divestitures (2022 - 2025)

Biofrontera (BFRI) has 4 years of Gains from Sales and Divestitures data on record, last reported at $225000.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 4615.99% year-over-year to $225000.0; the TTM value through Sep 2025 reached $225000.0, up 4615.99%, while the annual FY2024 figure was $4771.0, 44.45% down from the prior year.
  • Gains from Sales and Divestitures reached $225000.0 in Q3 2025 per BFRI's latest filing, up from $4771.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $170.1 million in Q2 2022 and bottomed at $4771.0 in Q2 2024.
  • Average Gains from Sales and Divestitures over 4 years is $18.9 million, with a median of $8588.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 94.95% in 2023, then skyrocketed 4615.99% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $8504.0 in 2022, then increased by 0.99% to $8588.0 in 2023, then crashed by 44.45% to $4771.0 in 2024, then surged by 4615.99% to $225000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $225000.0 in Q3 2025, $4771.0 in Q4 2024, and $4771.0 in Q3 2024.